Needham Reiterates Buy on Sarepta Therapeutics, Maintains $185 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $185 price target.
May 24, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Sarepta Therapeutics and maintains a $185 price target.
The reiteration of the Buy rating and maintenance of the $185 price target by Needham analyst Gil Blum indicates a positive outlook for Sarepta Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100